药明生物在爱尔兰开建公司首个海外生物制药生产基地 | Bilingual News

药明生物在爱尔兰开建公司首个海外生物制药生产基地

WuXi Biologics Commenced Construction of the Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland

(*Please scroll down for English news.)

爱尔兰敦多克，中国上海，2018年12月5日

全球领先的开放式生物制药技术平台公司药明生物（WuXi Biologics, 2269.HK）今日宣布在爱尔兰敦多克市正式开建生物制药生产基地。这是药明生物在中国境外投资建设的第一个生产基地，也是中国制药行业首屈一指的大规模海外建设新厂投资项目。

Amicus公司总裁兼首席运营官Bradley L. Campbell先生和药明生物首席执行官陈智胜博士共同植树庆祝新基地奠基

在爱尔兰政府及爱尔兰投资发展局（IDA）充分支持下，该基地将继续应用领先的一次性生物反应技术，采用传统流加生产工艺或灌流生产工艺，以及先进的“新一代生物制药生产技术”（连续生产工艺）开展商业化生产，有望成为全球领先的生物制药“未来工厂”。该基地总计新安装48000升流加细胞培养反应器与6000升灌流工艺生物反应器，有望成为世界上规模最大的使用一次性生物反应器的生物制药基地之一。

左起：Amicus公司首席科学家Hung Do博士，Amicus公司总裁兼首席运营官Bradley L. Campbell先生，药明生物副总裁、爱尔兰敦多克基地负责人 Brendan McGrath先生，Amicus公司全球供应链兼合作生产副总裁Jason Cameron先生，Amicus公司技术运营高级副总裁Enrique Diloné博士，药明生物首席执行官陈智胜博士，药明生物全球生产高级副总裁董健先生，药明生物首席技术官、高级副总裁周伟昌博士，药明生物高级主任乐运环先生

药明生物首席执行官陈智胜博士表示：“今天我们很高兴见证药明生物首个海外生产基地正式奠基，这将是药明生物国际化战略布局的起点和关键一环，确保公司生产的最高质量标准生物药通过强大的供应链网络造福全球病患。我们将与当地合作伙伴携手建设全球领先的新一代生物制药生产基地，成为爱尔兰打造全球生物技术中心的展示窗口。”

关于药明生物

药明生物（股票代码：2269.HK）作为一家香港上市公司，是全球领先的开放式、一体化生物制药能力和技术赋能平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务，帮助任何人、任何公司发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。截至2018年6月30日，在药明生物平台上研发的综合项目达187个，包括98个处于临床前研究阶段，78个在临床早期（I期，II期）阶段，10个在后期临床（III期）以及1个在商业化生产阶段。预计到2021年，公司在中国、爱尔兰、新加坡、美国规划的生物制药生产基地合计产能约22万升，这将有力确保公司通过健全强大的全球供应链网络为客户提供符合全球质量标准的生物药。如需更多信息，请访问：www.wuxibiologics.com.cn。

相关阅读

WuXi Biologics Commenced Construction of the Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland

DUNDALK Ireland and SHANGHAI China

December 5, 2018

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that the construction of new biologics drug substance manufacturing facility has commenced on the Industrial Development Authority’s (IDA) greenfield site in Mullagharlin, Dundalk, Co. Louth.

Bradley L. Campbell, President and Chief Operating Officer of Amicus and Dr. Chris Chen, Chief Executive Officer of WuXi Biologics planted a tree at the new site during the ceremony

Being the company’s first site outside of China which is supported by the Irish Government through IDA Ireland, this state-of-the-art “facility of the future” is designed to run both traditional fed-batch or perfusion process and continuous bioprocessing, a next generation manufacturing technology to be first implemented globally in this 26-hectare campus. When completed, a total capacity of 48,000L fed-batch and 6,000L perfusion will be installed, representing one of the world’s largest facility using single-use bioreactors.

From left to right: Dr. Hung Do, Chief Science Officer of Amicus, Bradley L. Campbell, President and Chief Operating Officer of Amicus, Brendan McGrath, Vice President, Head of Dundalk, Ireland Site of WuXi Biologics, Jason Cameron, Vice President of Global Supply Chain & External Manufacturing of Amicus, Dr. Enrique Diloné, Senior Vice President of Technical Operations of Amicus, Dr. Chris Chen, Chief Executive Officer of WuXi Biologics, Jian Dong, Senior Vice President, Global Biomanufacturing of WuXi Biologics, Dr. Weichang Zhou, Chief Technology Officer, Senior Vice President of WuXi Biologics, Thomas Yue, Senior Director of WuXi Biologics

“We are excited to witness the construction of WuXi Biologics’ first global site today,” commented Dr. Chris Chen, Chief Executive Officer of WuXi Biologics, “The commencement of this new facility symbolizes the significant start of our global biomanufacturing network to make sure that biologics can be manufactured at the highest quality, providing a robust supply chain to benefit patients worldwide. With this new project, we can actively work with all local partners to build this state-of-the-art biomanufacturing facility as a showcase to the entire global biotech community.”

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. As of June 30, 2018, there were a total of 187 integrated projects, including 98 projects in pre-clinical development stage, 78 projects in early-phase (phase I and II) clinical development, 10 projects in late-phase (phase III) development and 1 project in commercial manufacturing. With total estimated capacity of biopharmaceutical production planned in China, Ireland, Singapore and US reaching 220,000 liters by 2021, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit www.wuxibiologics.com.

注：本信息不构成药明生物的信息披露或投资建议